🚨 CRITICAL PATIENT SAFETY ISSUE
Antipsychotic medications carry a black box warning from the FDA for increased mortality risk in elderly patients with dementia-related psychosis. Despite this, they remain among the most commonly prescribed medications in older adults, frequently for off-label, inappropriate indications such as insomnia, anxiety, and mild behavioral symptoms. This article examines why this dangerous pattern persists and provides evidence-based alternatives.
Introduction: A Public Health Crisis
The question "Why are Seroquel (quetiapine) and risperidone prescribed so much in elderly people?" reveals one of the most significant medication safety issues in geriatric medicine. These antipsychotic medications—originally developed for schizophrenia and bipolar disorder—have become among the most frequently prescribed drugs in elderly populations, particularly in nursing homes and assisted living facilities. The troubling reality is that the vast majority of this prescribing is inappropriate, off-label, and potentially harmful.
Important clarification: Seroquel and quetiapine are the same medication. Seroquel is the brand name, while quetiapine is the generic name. This article addresses both quetiapine (Seroquel) and risperidone as representative examples of the broader problem of antipsychotic overuse in elderly populations.
The consequences of this overprescribing are severe: increased mortality, accelerated cognitive decline, increased falls and fractures, metabolic complications including diabetes and stroke, and diminished quality of life. Yet the practice continues, driven by a complex interplay of clinical, systemic, and economic factors that often override evidence-based medicine and patient safety.
💎 Key Clinical Point
Antipsychotics are never first-line treatment for insomnia, anxiety, agitation, or general behavioral disturbances in elderly patients. They should be reserved for specific psychiatric conditions or severe, refractory behavioral symptoms that pose imminent safety risk—and even then, only after comprehensive evaluation and trial of non-pharmacological approaches.
Epidemiology: The Scope of the Problem
Prescribing Prevalence Data
| Setting | Prevalence of Use | % Off-Label Use | Most Common Indications |
|---|---|---|---|
| Nursing Homes (US) | 25-40% | 75-85% | Agitation, sleep, "behavioral issues" |
| Assisted Living | 15-25% | 80-90% | Insomnia, anxiety, confusion |
| Community-Dwelling Elderly | 5-12% | 60-70% | Sleep, anxiety, depression augmentation |
| Dementia Patients (all settings) | 30-50% | 85-95% | BPSD, wandering, vocalizations |
| Hospital Discharge | 8-15% newly started | 70-80% | Delirium, agitation during hospitalization |
Quetiapine vs. Risperidone: Usage Patterns
While both medications are overused, they tend to be prescribed for somewhat different inappropriate indications, reflecting prescriber perceptions (often misconceptions) about their safety and efficacy profiles.
Quetiapine (Seroquel) - Most Common Misuses
- Insomnia: The #1 off-label use, particularly low-dose (25-100mg qhs)
- Anxiety: General anxiety, particularly in patients who "failed" benzodiazepines
- Agitation in dementia: Often first-line despite lack of efficacy
- Depression augmentation: Sometimes appropriate, often reflexive
- Delirium management: Widespread despite lack of evidence
Perceived (false) advantage: "Safer" than other antipsychotics, "less extrapyramidal symptoms," "helps with sleep"
Risperidone - Most Common Misuses
- Behavioral symptoms in dementia: Aggression, agitation
- Psychotic symptoms in dementia: Hallucinations, delusions
- Nursing home agitation: "Disruptive" behaviors
- Post-stroke agitation: Common but dangerous
- Sundowning: Evening confusion/restlessness
Perceived (false) advantage: "More effective for behavioral control," available in liquid/injectable forms, "quick-acting"
⚠️ Reality Check
Neither quetiapine nor risperidone has compelling evidence of efficacy for the majority of indications for which they are prescribed in elderly patients. The perceived differences in safety between them are minimal—both carry serious risks in older adults. The choice of one over the other is often based on tradition, familiarity, or formulary considerations rather than evidence.
Temporal Trends: Getting Worse, Not Better
Despite increased awareness of risks, regulatory warnings, and quality improvement initiatives, antipsychotic use in elderly populations has not substantially declined and in some settings has increased. Several concerning trends include the shift from conventional to atypical antipsychotics (often without reduction in total use), increased use of quetiapine for off-label indications particularly insomnia, "chemical restraint" in understaffed facilities, and prescription continuation despite initial indications resolving.
Why Are These Medications So Overprescribed?
The widespread inappropriate use of antipsychotics in elderly patients is not due to a single cause but rather results from a complex web of clinical, systemic, economic, and educational factors. Understanding these drivers is essential for addressing the problem.
Factor 1: Symptomatic Effectiveness for Common Problems
Antipsychotics do work—at least in the short term—for many common symptoms in elderly patients. Quetiapine's sedating properties make it effective for initiating sleep. Risperidone can rapidly calm agitated patients. This immediate symptomatic relief is highly reinforcing for prescribers, even when the long-term risks far outweigh short-term benefits. The problem is that effectiveness does not equal appropriateness. Many dangerous medications are effective for off-label uses, but we don't use them because the risk-benefit ratio is unfavorable.
📋 Typical Clinical Scenario
Situation: An 82-year-old nursing home resident with mild dementia has difficulty sleeping and wanders at night. Night staff are concerned about fall risk.
Inappropriate response: Prescriber orders quetiapine 25mg qhs. Patient sleeps better, wandering decreases. Problem "solved."
What wasn't considered: Why is the patient wandering? (pain, need to urinate, boredom, excess daytime napping). Are there environmental modifications? (night lights, secured wandering path, activity during day, scheduled toileting). What are the long-term risks? (falls, cognitive decline, metabolic effects, stroke).
Outcome: Six months later, patient experiences fall with hip fracture. Quetiapine is continued post-fracture because discontinuation "might make agitation worse."
Factor 2: Prescriber Perception of Safety
Many prescribers, particularly those who completed training before widespread recognition of antipsychotic risks in elderly patients, maintain outdated beliefs about these medications. Common dangerous misconceptions include the idea that quetiapine is "safer" than other antipsychotics because it causes fewer extrapyramidal symptoms at low doses, that "low-dose" antipsychotics (quetiapine 25-50mg) are benign or even safer than alternatives like benzodiazepines, that atypical antipsychotics are safer than conventional ones in elderly patients, and that the black box warning only applies to "high doses" or "demented patients."
The reality is that the black box warning for increased mortality applies to all doses and all elderly patients with dementia, not just high doses. Even low-dose quetiapine carries metabolic, cognitive, and cardiovascular risks. The distinction between "typical" and "atypical" antipsychotics is clinically less meaningful than previously believed, particularly regarding safety in elderly patients.
Factor 3: Limited Time and Resources for Non-Pharmacological Approaches
Evidence-based non-pharmacological interventions for insomnia, agitation, and behavioral symptoms in elderly patients are time-intensive and resource-heavy. They require comprehensive assessment (identifying pain, infection, environmental triggers, unmet needs), staff training, environmental modifications, and ongoing monitoring and adjustment. In contrast, writing a prescription takes seconds and provides immediate relief to stressed staff or family caregivers.
This is particularly problematic in understaffed nursing homes where one nurse may be responsible for 30+ residents on a night shift. When an agitated patient is "disrupting" other residents, pharmacological sedation is often seen as the only feasible option, even though it may not be the most appropriate one.
⚠️ Ethical Consideration
Using antipsychotics primarily for staff or institutional convenience rather than patient benefit crosses into the territory of "chemical restraint"—a practice that is both ethically problematic and, in many jurisdictions, legally restricted. The Centers for Medicare & Medicaid Services (CMS) has specific regulations limiting antipsychotic use in nursing homes, yet enforcement is often inadequate.
Factor 4: Diagnostic Uncertainty and Lack of Psychiatric Expertise
Many primary care providers and hospitalists lack confidence in diagnosing and managing psychiatric conditions in elderly patients. When faced with an elderly patient with behavioral symptoms, the differential diagnosis is broad and the evaluation is complex. Rather than conducting thorough assessment or obtaining psychiatric consultation, prescribers may default to antipsychotic prescription as a "trial" that becomes permanent.
Common diagnostic errors include mistaking delirium for dementia or primary psychiatric illness, failure to recognize underlying medical causes of behavioral symptoms (pain, infection, constipation, medication effects), over-diagnosing psychosis in patients with sensory impairment or communication difficulties, and attributing all behavioral symptoms in dementia patients to the dementia itself rather than investigating reversible causes.
Factor 5: Prescription Inertia and Continuation
Once started, antipsychotics tend to continue indefinitely. Studies show that over 70% of elderly patients started on antipsychotics in hospitals or nursing homes remain on them long after the initial indication has resolved—if there ever was an appropriate indication. The reasons for continuation include the assumption that "the patient needs it" without reassessment, fear that discontinuation will cause symptom recurrence, lack of time or systems for systematic medication review, and transfer of patients between care settings without medication reconciliation or questioning of appropriateness.
Factor 6: Marketing and Historical Prescribing Patterns
Although direct-to-physician marketing has decreased, the legacy of aggressive pharmaceutical promotion continues to influence prescribing. Quetiapine in particular was heavily marketed for off-label uses before regulatory crackdowns, creating prescribing patterns that persist today. Many prescribers learned from mentors who prescribed these medications liberally and continue those patterns without questioning them.
Factor 7: Family and Caregiver Pressure
Family members and caregivers, understandably distressed by their loved one's behavioral symptoms or sleep disturbances, often request "something to help." In the absence of readily available non-pharmacological supports, prescribers may acquiesce to these requests even when knowing the prescription is not ideal. This is compounded when families threaten to transfer patients to different facilities or providers if symptoms are not "controlled."
💎 Clinical Pearl
The question "Why are antipsychotics overprescribed in elderly patients?" ultimately comes down to: they work quickly for common problems, prescribers underestimate risks, non-pharmacological alternatives are time-intensive, and systemic factors (staffing, resources, time constraints) favor quick pharmacological fixes over comprehensive care. Addressing the problem requires changes at clinical, institutional, and policy levels.
Risks and Harms: Why This Matters
⚠️ FDA BLACK BOX WARNING
Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times that of placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
These drugs are NOT approved for the treatment of dementia-related psychosis.
Mortality Risk: The Most Serious Concern
The black box warning is based on compelling evidence from multiple randomized controlled trials and large observational studies. The increased mortality risk is real, substantial, and applies to all atypical antipsychotics including quetiapine and risperidone. The number needed to harm (NNH) is approximately 50-100, meaning for every 50-100 elderly dementia patients treated with antipsychotics for 10 weeks, one additional death occurs compared to placebo.
Importantly, observational studies suggest the mortality risk extends beyond the 10-week trial period and may be even higher with longer-term use. The risk is dose-dependent but present even at low doses. Conventional (typical) antipsychotics may carry equal or greater mortality risk than atypical agents.
Cerebrovascular Events (Stroke)
Antipsychotics, particularly risperidone, are associated with 2-3 fold increased risk of stroke in elderly patients with dementia. Mechanisms include increased platelet aggregation, orthostatic hypotension leading to hypoperfusion, sedation-related aspiration and pneumonia, atrial fibrillation, and metabolic effects (diabetes, dyslipidemia). The risk appears highest in the first weeks of treatment but persists with continued use.
| Adverse Effect | Quetiapine Risk | Risperidone Risk | Clinical Impact |
|---|---|---|---|
| Mortality | RR 1.5-2.0 | RR 1.6-2.5 | NNH ~50-100 over 10 weeks |
| Stroke/CVA | RR 1.5-2.0 | RR 2.0-3.0 | Particularly high in first 30 days |
| Falls | RR 1.4-2.0 | RR 1.3-1.8 | Dose-dependent; worst with initiation |
| Cognitive Decline | Moderate-High | Moderate-High | May be irreversible with prolonged use |
| Metabolic Syndrome | High (weight gain, diabetes) | Moderate-High | Quetiapine particularly problematic |
| Pneumonia | RR 1.3-1.8 | RR 1.5-2.0 | Via sedation, dysphagia, aspiration |
| QTc Prolongation | Moderate | Low-Moderate | Increased sudden death risk |
| Extrapyramidal Symptoms | Low (dose-dependent) | Moderate-High | Parkinsonism, dyskinesia, akathisia |
Falls and Fractures
Antipsychotics increase fall risk through multiple mechanisms including sedation and psychomotor slowing, orthostatic hypotension, extrapyramidal symptoms (rigidity, bradykinesia), impaired judgment and spatial awareness, and gait disturbances. In elderly patients, who often have baseline fall risk from multiple factors, even small increases in fall risk translate to substantial numbers of fractures, hospitalizations, and functional decline.
Cognitive Decline
Antipsychotics have anticholinergic properties (particularly quetiapine at higher doses) that directly impair cognition. In patients with dementia, antipsychotics may accelerate cognitive decline beyond the natural progression of the disease. Some evidence suggests prolonged antipsychotic use may increase risk of developing dementia in patients without baseline cognitive impairment. The cognitive impairment from antipsychotics may be partially reversible with discontinuation, but some effects may persist, particularly with long-term use.
🚨 Special Risk in Cardiovascular Patients
For cardiologists and internists managing elderly cardiac patients: Antipsychotics carry particular risks in patients with cardiovascular disease. They can cause QTc prolongation (especially quetiapine, risperidone), orthostatic hypotension worsening heart failure symptoms, weight gain and metabolic syndrome accelerating atherosclerosis, sedation interfering with cardiac rehabilitation, and increased risk of sudden cardiac death. Always review medication lists in elderly cardiac patients and question any antipsychotic prescriptions, particularly for off-label indications.
Metabolic Effects
Quetiapine and risperidone are associated with significant metabolic adverse effects in elderly patients. Weight gain (more pronounced with quetiapine) increases cardiovascular risk and complicates diabetes management. New-onset diabetes or worsening glycemic control is common, particularly with quetiapine. Dyslipidemia with increased triglycerides and LDL cholesterol occurs frequently. These metabolic effects compound pre-existing cardiovascular risk in elderly populations.
Pneumonia and Aspiration
Antipsychotics increase pneumonia risk through sedation leading to decreased mobility and secretion clearance, dysphagia (swallowing difficulties) particularly with risperidone, suppression of cough reflex, and reduced awareness of aspiration risk during eating. Pneumonia is a leading cause of death in elderly patients with dementia, and antipsychotics substantially increase this already-elevated risk.
When ARE Antipsychotics Appropriate in Elderly Patients?
Despite the extensive risks, antipsychotics do have legitimate roles in geriatric medicine. The key is ensuring use is limited to appropriate indications, at the lowest effective dose, for the shortest duration necessary, with careful monitoring and regular reassessment.
✓ Evidence-Supported Indications
- Schizophrenia: Continuing treatment in elderly patients with established schizophrenia (though dose reduction often appropriate with aging)
- Bipolar Disorder (Acute Mania): During acute manic episodes, though mood stabilizers preferred for maintenance
- Severe, Refractory BPSD: When behavioral and psychological symptoms of dementia (BPSD) pose imminent risk of harm to self or others AND have not responded to comprehensive non-pharmacological interventions and treatment of underlying causes
- Psychosis in Parkinson's Disease: Quetiapine specifically may be used (pimavanserin preferred if available)
- Delusional Disorder: Persistent delusions causing significant functional impairment or distress
- Psychotic Depression: As adjunct to antidepressant therapy when psychotic features present
✗ Inappropriate Uses (Common But Not Evidence-Based)
- Insomnia: One of the most common misuses, particularly quetiapine 25-100mg qhs. No evidence supports this use; significant risks for minimal benefit
- Generalized Anxiety: Not effective and risks outweigh benefits; many safer alternatives available
- Mild BPSD: Restlessness, wandering, repetitive vocalizations that don't pose safety risk
- Delirium: No evidence of efficacy; may prolong delirium and worsen outcomes
- "Sundowning": Evening confusion/agitation that is better addressed through environmental and behavioral approaches
- Depression (Monotherapy): Antipsychotics alone are not effective antidepressants in elderly
- Dementia-Related Behaviors (First-Line): Should never be first-line; only after comprehensive evaluation and trial of alternatives
- Convenience or "Chemical Restraint": Using sedation to manage behaviors primarily for staff convenience
Appropriate Use Criteria: A Decision Framework
Before prescribing an antipsychotic to an elderly patient, the following criteria should be met:
Is there a specific psychiatric diagnosis (schizophrenia, bipolar disorder, psychotic depression) or severe, dangerous BPSD? If the indication is insomnia, anxiety, or mild behavioral symptoms → STOP. Antipsychotic is inappropriate.
Has a comprehensive evaluation been done to identify and address: pain, infection (UTI, pneumonia), metabolic disturbances, medication effects (anticholinergics, opioids, benzodiazepines), constipation, urinary retention, environmental factors (noise, temperature, overstimulation)? Treat all identified reversible causes first.
Have evidence-based behavioral interventions been attempted? For agitation: music therapy, validation therapy, structured activities, environmental modification. For sleep: sleep hygiene, light therapy, scheduled toileting, pain management. These should be tried for at least 2 weeks before pharmacological intervention.
If pharmacological intervention is necessary, have safer alternatives been considered? For depression with agitation: antidepressants (especially SSRIs). For severe anxiety: low-dose SSRIs or buspirone. For insomnia: low-dose trazodone or melatonin. For aggression in dementia: consider memantine, SSRIs, or anticonvulsants before antipsychotics.
If antipsychotic is deemed necessary: Discuss risks vs. benefits with patient (if able) and family/surrogate. Document specific target symptoms, planned duration of treatment, and monitoring plan. Acknowledge off-label use if applicable. Consider alternatives discussed and reasons for choosing antipsychotic.
Use lowest possible dose (quetiapine 12.5-25mg, risperidone 0.25-0.5mg to start). Set specific treatment endpoint (e.g., "trial for 2 weeks for severe agitation"). Schedule reassessment within 2-4 weeks. Monitor closely for adverse effects. Plan for gradual discontinuation once target symptoms improve.
💎 Clinical Pearl
If you cannot articulate a specific, appropriate indication for an antipsychotic (beyond "agitation," "insomnia," or "behavioral issues"), and if you cannot identify what specific target symptom you will use to monitor response and determine when to discontinue, the medication should not be started. Vague indications lead to indefinite, inappropriate continuation.
Evidence-Based Alternatives to Antipsychotics
For the majority of situations where antipsychotics are currently prescribed in elderly patients, safer and often more effective alternatives exist. The challenge is that these alternatives generally require more effort, time, and resources than simply writing a prescription.
For Insomnia (The #1 Inappropriate Use of Quetiapine)
First-Line Approaches
- Sleep Hygiene: Consistent sleep schedule, quiet/dark environment, avoid daytime napping >30min
- Cognitive Behavioral Therapy for Insomnia (CBT-I): Most effective long-term treatment
- Treat Underlying Causes: Pain, nocturia, sleep apnea, restless legs, medication effects
- Light Therapy: Bright light exposure during day for circadian regulation
- Exercise: Regular physical activity improves sleep (avoid close to bedtime)
Pharmacological Options (If Non-Pharm Fails)
- Melatonin: 0.5-3mg 1-2 hours before bedtime (prolonged-release formulations may be better)
- Trazodone: 25-50mg qhs (lower risk than antipsychotics, though still has risks)
- Ramelteon: 8mg qhs (melatonin receptor agonist)
- Mirtazapine: 7.5-15mg qhs (if comorbid depression or poor appetite)
- Avoid: Benzodiazepines, antihistamines (diphenhydramine), quetiapine
For Behavioral and Psychological Symptoms of Dementia (BPSD)
BPSD includes agitation, aggression, wandering, repetitive vocalizations, hallucinations, and delusions. Non-pharmacological approaches should always be first-line.
Systematic Approach to BPSD
- Identify and Treat Triggers:
- Pain assessment and management (use observational pain scales in non-verbal patients)
- Screen for infection (especially UTI, pneumonia)
- Review medications for culprits (anticholinergics, sedatives, corticosteroids)
- Environmental assessment (noise, temperature, overstimulation, under-stimulation)
- Unmet needs (hunger, thirst, need to toilet, boredom, loneliness)
- Non-Pharmacological Interventions:
- Music therapy (particularly music from patient's young adulthood)
- Validation therapy (acknowledge feelings rather than argue with delusions)
- Aromatherapy (lavender, chamomile may reduce agitation)
- Pet therapy or robotic pets
- Structured daily activities and routine
- Environmental modification (reduce stimulation, improve lighting, create safe wandering paths)
- Caregiver education and support
- Pharmacological Approaches (Before Antipsychotics):
- Cholinesterase Inhibitors: Donepezil, rivastigmine, galantamine (for patients not already on them; may reduce BPSD)
- Memantine: Some evidence for reducing agitation in moderate-severe dementia
- SSRIs: Citalopram 10-20mg or sertraline 25-100mg for depression, anxiety, or irritability in dementia
- Anticonvulsants: Valproic acid or carbamazepine for aggression (though evidence mixed and side effects significant)
- Analgesics: Regular scheduled acetaminophen may reduce agitation if pain is unrecognized cause
⚠️ Important Note on SSRI Use in BPSD
While citalopram has been studied for agitation in dementia and shows modest efficacy, high doses (>20mg daily) are associated with QTc prolongation and should be avoided in elderly patients. Use the minimum effective dose and monitor ECG if cardiovascular risk factors present.
For Anxiety
Non-Pharmacological
- Cognitive Behavioral Therapy (adapted for elderly)
- Relaxation techniques, mindfulness
- Exercise programs
- Social engagement and activities
- Address underlying medical causes
Pharmacological (Safer Than Antipsychotics)
- SSRIs: Escitalopram 5-10mg, sertraline 25-100mg (first-line)
- SNRIs: Venlafaxine XR 37.5-75mg
- Buspirone: 5-15mg BID-TID (takes weeks to work; no dependence risk)
- Hydroxyzine: 12.5-25mg PRN (short-term only; anticholinergic concerns)
- Avoid: Benzodiazepines for chronic anxiety, quetiapine
For Delirium
This is particularly important because antipsychotics are frequently used for delirium despite lack of evidence for efficacy and potential for harm.
💎 Critical Point on Delirium Management
Multiple high-quality RCTs have shown that antipsychotics do NOT reduce duration or severity of delirium and may worsen outcomes. The mainstay of delirium management is identifying and treating the underlying cause (infection, medication effects, metabolic disturbances, pain) combined with non-pharmacological approaches (reorientation, mobilization, sensory aids, sleep-wake cycle regulation). Antipsychotics should be reserved only for severe agitation posing immediate safety risk, at lowest dose, for shortest duration.
Evidence-Based Delirium Management
- Systematic search for and treatment of underlying causes
- Medication review and elimination of culprits (especially anticholinergics, benzodiazepines, opioids)
- Non-pharmacological bundle: reorientation, early mobilization, hearing/visual aids, sleep hygiene, adequate nutrition/hydration
- Family presence and familiar objects from home
- Avoid physical restraints (often worsen delirium and agitation)
- Reserve pharmacological sedation for severe, dangerous agitation only; minimize duration
Deprescribing: How to Safely Discontinue Inappropriate Antipsychotics
Given the high prevalence of inappropriate antipsychotic use, deprescribing is one of the most important interventions to improve safety and quality of care in elderly patients. Multiple studies demonstrate that antipsychotics can be successfully discontinued in the majority of elderly patients without worsening of symptoms, and many patients actually improve after discontinuation.
Evidence for Deprescribing
- 60-80% of elderly patients can successfully discontinue antipsychotics without symptom recurrence
- Many patients show improvement in cognition, alertness, and quality of life after discontinuation
- Risk of falls, fractures, and other adverse events decreases after discontinuation
- Systematic deprescribing programs in nursing homes have successfully reduced antipsychotic use by 30-50%
Step-by-Step Deprescribing Protocol
High-priority candidates:
- Any patient on antipsychotic for off-label indication (insomnia, anxiety, mild BPSD)
- Patients who have been stable on antipsychotic for >3 months without clear ongoing indication
- Patients experiencing side effects (sedation, falls, cognitive impairment, metabolic effects)
- Patients with no documented indication or target symptoms in chart
Lower priority but still consider:
- Patients on high doses who might benefit from dose reduction
- Patients on multiple psychotropic medications
Before initiating deprescribing:
- Document current target symptoms (if any) using validated scales (Cohen-Mansfield Agitation Inventory, Neuropsychiatric Inventory)
- Assess current functional status, cognition (if possible), quality of life
- Review all medications for potential interactions or other psychotropics
- Discuss plan with patient/family, address concerns about symptom recurrence
- Engage multidisciplinary team (nursing, therapy staff) in monitoring
General tapering schedule:
- Quetiapine: Reduce by 25mg every 1-2 weeks (e.g., 50mg → 25mg → 12.5mg → discontinue)
- Risperidone: Reduce by 0.25mg every 1-2 weeks (e.g., 1mg → 0.75mg → 0.5mg → 0.25mg → discontinue)
- Slower tapers (every 2-4 weeks) may be appropriate for patients on antipsychotics >1 year or at higher doses
- Monitor closely for withdrawal symptoms (insomnia, nausea, agitation) during taper
Special considerations:
- In stable patients on very low doses (quetiapine 25mg, risperidone 0.25mg) for non-psychiatric indications, consider direct discontinuation rather than taper
- Some patients may benefit from even slower tapers (10% reduction every 2-4 weeks)
Monitoring schedule:
- Weekly assessment of target symptoms during active taper
- Monitor for withdrawal symptoms, recurrence of psychiatric symptoms, changes in function
- Regular communication with nursing staff, family, caregivers
- Document response at each dose reduction
Non-pharmacological support during deprescribing:
- Ensure adequate treatment of pain, constipation, other physical symptoms that might trigger behavioral symptoms
- Implement or intensify behavioral interventions (especially if symptoms were being "masked" by medication)
- Increase social engagement, meaningful activities
- Environmental modifications as needed
If withdrawal symptoms occur:
- Slow the taper (smaller reductions, longer intervals between reductions)
- Provide symptomatic support (e.g., melatonin for insomnia, antiemetics for nausea)
- Reassure patient/family that withdrawal symptoms are temporary
If target psychiatric symptoms recur:
- Assess whether recurrence is true symptom return vs. withdrawal, rebound, or new stressor
- Intensify non-pharmacological interventions
- Consider whether symptoms represent safety risk or are manageable
- If symptoms pose clear safety risk: pause taper, stabilize, then resume more gradually
- If symptoms are mild-moderate: continue taper while supporting with behavioral approaches
When to resume antipsychotic:
- Severe, dangerous agitation or psychosis that poses imminent risk of harm
- Symptoms that significantly impair quality of life and do not respond to alternatives
- Document clearly why resumption was necessary and what alternatives were attempted
After successful discontinuation:
- Continue monitoring for 1-3 months (symptoms may recur after initial success)
- Document successful discontinuation and alternatives used
- Educate patient/family/staff about non-pharmacological management to prevent re-initiation
- If patient transfers to another setting, clearly communicate that antipsychotic was successfully discontinued and should not be restarted without clear indication
Common Barriers to Deprescribing and Solutions
| Barrier | Solution/Strategy |
|---|---|
| Family or staff fear of symptom recurrence | Education about risks of continued use, evidence for successful deprescribing, shared decision-making, clear monitoring plan with "safety net" if needed |
| "The patient needs it" assumption | Review original indication (often no longer relevant or never appropriate), trial discontinuation to test assumption |
| Lack of time or resources for monitoring | Use existing staff (nursing, therapy) with clear protocols, focus on patients most likely to succeed, demonstrate time saved by avoiding fall injuries and complications |
| Prescriber inertia or reluctance | Provide evidence, quality improvement initiatives, peer comparison data, regulatory/accreditation pressures |
| Withdrawal symptoms misinterpreted as symptom recurrence | Education about withdrawal timeline (usually 1-2 weeks), slower taper, symptomatic management |
| Concurrent stressors (facility change, illness, bereavement) | Delay deprescribing until patient is stable, address stressors concurrently, slower taper during stressful periods |
💎 Clinical Pearl
The best predictor of successful deprescribing is prescriber commitment. When the clinical team is convinced that deprescribing is important and feasible, success rates are high. Conversely, if the team is skeptical or fearful, minor challenges may be interpreted as "failure" and lead to resumption. Frame deprescribing as an intervention to improve patient safety and quality of life, not as "taking away" a medication.
Summary: Key Takeaways for Clinical Practice
🎯 Essential Points
- The Problem: 25-40% of elderly patients in nursing homes receive antipsychotics, with 75-85% of use being off-label and inappropriate
- Most Common Misuses: Insomnia (especially quetiapine), anxiety, mild behavioral symptoms in dementia, delirium
- Why It Happens: Quick symptom relief, prescriber misconceptions about safety, limited resources for alternatives, diagnostic uncertainty, prescription inertia
- The Risks: Increased mortality (RR 1.5-2.0), stroke (RR 2-3), falls/fractures, cognitive decline, metabolic effects, pneumonia
- Appropriate Use: Limited to specific psychiatric diagnoses (schizophrenia, bipolar disorder) or severe, dangerous BPSD after comprehensive evaluation and trial of alternatives
- Safer Alternatives: Non-pharmacological interventions (always first-line), targeted treatment of underlying causes, medication alternatives (melatonin, trazodone for sleep; SSRIs for anxiety/depression; memantine for BPSD)
- Deprescribing: 60-80% of patients can successfully discontinue antipsychotics with gradual taper, close monitoring, and non-pharmacological support
Action Items for Prescribers
- Review your patient panel: Identify all elderly patients on quetiapine, risperidone, or other antipsychotics
- Question every prescription: Is there a clear, appropriate indication? Has it been documented? Is it still relevant?
- Stop inappropriate new starts: Before prescribing an antipsychotic for an elderly patient, go through the decision framework in this article
- Implement systematic deprescribing: Start with the "easiest" cases (low-dose quetiapine for insomnia) and build confidence
- Educate colleagues and staff: Share this information with nursing, pharmacy, and other prescribers
- Use alternatives: Become comfortable with non-pharmacological approaches and safer medication alternatives
- Document clearly: When antipsychotics are truly necessary, document specific indications, target symptoms, and planned duration
For Cardiologists Specifically
Antipsychotic use is a cardiovascular risk factor that often goes unrecognized. When seeing elderly cardiac patients:
- Review medication lists for quetiapine, risperidone, and other antipsychotics
- Question indications, especially if prescribed for "sleep" or "anxiety"
- Consider antipsychotics when evaluating unexplained weight gain, new-onset diabetes, or worsening metabolic syndrome
- Check QTc in patients on antipsychotics, especially if other QT-prolonging medications present
- Advocate for deprescribing when antipsychotics are inappropriate
- Educate patients/families about cardiovascular risks of these medications
🚨 Final Message
The overuse of antipsychotics in elderly patients represents a serious, ongoing patient safety crisis. These medications carry significant risks including increased mortality, yet they are routinely prescribed for indications where they lack efficacy and safer alternatives exist. Every prescriber has a responsibility to question current practices, implement safer alternatives, and actively deprescribe inappropriate antipsychotics. The evidence is clear: reducing antipsychotic use in elderly patients saves lives and improves quality of life.
Key References and Further Reading
- Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943.
- Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786.
- Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438-445.
- Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157.
- Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
- American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694.
- Tampi RR, Tampi DJ, Balachandran S, et al. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229-245.
- Thompson Coon J, Abbott R, Rogers M, et al. Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J Am Med Dir Assoc. 2014;15(10):706-718.
- Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.
- Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734.
- Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254-1268.
- Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;(3):CD007726.